|Other names||BAY-1002670; 17β-Hydroxy-11β-[4-(methylsulfonyl)phenyl]-17α-(1,1,2,2,2-pentafluoroethyl)estra-4,9-dien-3-one|
|Drug class||Selective progesterone receptor modulator|
|Chemical and physical data|
|Molar mass||544.58 g·mol−1|
|3D model (JSmol)|
Vilaprisan (INN, USAN) (developmental code name BAY-1002670) is a synthetic and steroidal selective progesterone receptor modulator (SPRM) which is under development by Bayer HealthCare Pharmaceuticals for the treatment of endometriosis and uterine fibroids. It is a potent and highly selective partial agonist of the progesterone receptor (PR). As of 2017, the drug is in phase II clinical trials for the aforementioned indications.
|This article about a steroid is a stub. You can help Wikipedia by expanding it.|
|This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.|